Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT02979392 Terminated - Clinical trials for Advanced Solid Tumor

Phase I Study of TENPA in Advanced Solid Cancer

Start date: May 2, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety and to determine maximum tolerated dose and recommended phase 2 dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in patients with advanced solid tumor.

NCT ID: NCT02553499 Terminated - Clinical trials for Advanced Solid Tumor

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Start date: November 12, 2015
Phase: Phase 1
Study type: Interventional

In this study, participants with advanced solid tumors were assigned to receive escalating doses of either MK-1248 alone or MK-1248 in combination with pembrolizumab (MK-3475). This study used the number of dose-limiting toxicities (DLTs) at each dose level to find and confirm the maximum tolerated dose (or maximum administered dose) for MK-1248 alone and in combination with pembrolizumab.

NCT ID: NCT02189174 Terminated - Clinical trials for Advanced Solid Tumor

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

Start date: August 7, 2014
Phase: Phase 1
Study type: Interventional

To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457

NCT ID: NCT02168725 Terminated - Neoplasms Clinical Trials

Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors

Start date: June 2014
Phase: Phase 1
Study type: Interventional

The main objectives of this study are to determine the safety profile of briciclib, an experimental anti-cancer drug, as it is administered intravenously once weekly as escalating doses in adult patients with advanced cancer and solid tumors, and to determine the highest dose of briciclib that can be safely given. Secondary objectives are to determine how the amount of briciclib in circulation changes over time and how much briciclib gets into the urine for excretion, and to document potential anti-tumor effects of briciclib.

NCT ID: NCT01378377 Terminated - Clinical trials for Advanced Solid Tumor

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Start date: May 27, 2011
Phase: Phase 1
Study type: Interventional

The research trial is testing the experimental drug pimasertib and the drug Torisel, given together, in the treatment of advanced solid tumors. The primary purpose of the study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of the drug combination.

NCT ID: NCT01131364 Terminated - Breast Cancer Clinical Trials

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Start date: June 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase Ib/II study is an openlabel, multicenter study for patients with solid tumors and breast cancer amenable to anthracyclin therapy. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with doxorubicin for patients with solid tumors. Phase II: a prospective, single-arm, multicentre study of a fixed dose of F16IL2 in combination with doxorubicin, equivalent to stage 1 of the Simon two-stage phase II design, for patients with breast cancer amenable to anthracyclin therapy.

NCT ID: NCT00742105 Terminated - Cancer Clinical Trials

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Start date: November 17, 2008
Phase: Phase 1
Study type: Interventional

This study will confirm safety and tolerability and determine the MTD of BGT226 in Japanese patients with advanced solid tumor.